GlaxoSmithKline Pharmaceuticals Ltd
GlaxoSmithKline Pharmaceuticals Ltd (GLAXO) last traded at ₹2,952, a market capitalisation of ₹50,011 crore, on a P/E of 47.5. Over the past 52 weeks the stock has ranged between ₹2,088 and ₹3,055. GlaxoSmithKline Pharmaceuticals Ltd last reported results for the quarter ended Jun 2026, with sales of ₹938 crore and net profit of ₹237 crore. GlaxoSmithKline Pharmaceuticals Ltd’s annual general meeting is scheduled for 13 Sept 2026. Figures are as of 25 Aug 2026 and are not real time.
GlaxoSmithKline Pharmaceuticals Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
GlaxoSmithKline Pharmaceuticals Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹938 cr, up 16.5% from ₹805 cr a year earlier. Net profit was ₹237 cr, up 15.6% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1,011 | 949 | 974 | 805 | 980 | 1,041 | 995 | 938 |
| Expenses | 689 | 658 | 641 | 554 | 644 | 670 | 644 | 643 |
| Operating profit | 322 | 292 | 333 | 251 | 336 | 371 | 351 | 296 |
| OPM % | 32% | 31% | 34% | 31% | 34% | 36% | 35% | 31% |
| Other income | 39 | 35 | 41 | 44 | 36 | 50 | 36 | 44 |
| Interest | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 |
| Depreciation | 17 | 19 | 15 | 16 | 17 | 20 | 13 | 16 |
| Profit before tax | 344 | 308 | 359 | 279 | 354 | 400 | 373 | 322 |
| Tax % | 27% | 25% | 27% | 27% | 27% | 26% | 26% | 26% |
| Net profit | 252 | 230 | 263 | 205 | 257 | 296 | 278 | 237 |
| EPS (₹) | 14.91 | 13.57 | 15.52 | 12.10 | 15.20 | 17.45 | 16.40 | 14.00 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
GlaxoSmithKline Pharmaceuticals Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 2,926 | 3,278 | 3,252 | 3,454 | 3,749 | 3,822 | 3,955 |
| Operating profit | 598 | 762 | 804 | 909 | 1,179 | 1,309 | 1,354 |
| OPM % | 20% | 23% | 25% | 26% | 31% | 34% | 34% |
| Net profit | 358 | 1,695 | 611 | 590 | 928 | 1,036 | 1,068 |
| EPS (₹) | 21.14 | 100.04 | 36.05 | 34.83 | 54.75 | 61.15 | 63.05 |
TTM is the trailing twelve months to the most recent quarter.
GlaxoSmithKline Pharmaceuticals Ltd growth and returns
- 10 Years
- 3%
- 5 Years
- 5%
- 3 Years
- 6%
- TTM
- 6%
- 10 Years
- 10%
- 5 Years
- 15%
- 3 Years
- 18%
- TTM
- 11%
- 10 Years
- 7%
- 5 Years
- 14%
- 3 Years
- 27%
- 1 Year
- 5%
- 10 Years
- 33%
- 5 Years
- 48%
- 3 Years
- 43%
- Last Year
- 46%
GlaxoSmithKline Pharmaceuticals Ltd shareholding pattern
Promoters held 75.00% at Jun 2026, broadly unchanged since Jun 2025. FIIs 4.79% and DIIs 7.81%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% |
| FIIs | 4.36% | 4.50% | 4.52% | 4.89% | 4.79% | 4.63% | 4.62% | 4.79% |
| DIIs | 7.34% | 7.30% | 7.79% | 7.71% | 7.75% | 7.70% | 7.68% | 7.81% |
| Government | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 13.30% | 13.21% | 12.69% | 12.41% | 12.45% | 12.67% | 12.69% | 12.42% |
| No. of shareholders | 1,19,228 | 1,19,625 | 1,21,885 | 1,23,629 | 1,22,904 | 1,22,460 | 1,21,763 | 1,26,087 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
When is GlaxoSmithKline Pharmaceuticals Ltd’s AGM?
GlaxoSmithKline Pharmaceuticals Ltd’s annual general meeting is scheduled for 13 Sept 2026.
- AGMAppointment of Non-Executive Director and Re-appointment of Managing Director
See the full results calendar for every Indian company reporting in the next 30 days.
GlaxoSmithKline Pharmaceuticals Ltd corporate filings
- Disclosure Under Regulation 30Company Updatelow impact
Cruxal's analysis: The company has filed a routine disclosure under Regulation 30 of the SEBI (Listing…
Read the full analysis - Announcement under Regulation 30 (LODR)-Newspaper PublicationCompany Updatelow impact
Cruxal's analysis: The company has published its financial results in newspapers as per Regulation 30 of the…
Read the full analysis - Shareholder Meeting / Postal Ballot-Notice of Postal BallotAGM/EGMlow impact
Cruxal's analysis: GlaxoSmithKline Pharmaceuticals Limited has issued a Postal Ballot notice seeking…
Read the full analysis - TranscriptCompany Updatelow impact
Cruxal's analysis: GlaxoSmithKline Pharmaceuticals Ltd has filed the transcript of its recent…
Read the full analysis - IT Refund of Rs 52 croresCompany Updatelow impact
Cruxal's analysis: GlaxoSmithKline Pharmaceuticals Ltd has disclosed the receipt of an income tax refund…
Read the full analysis - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeCompany Updatelow impact
Cruxal's analysis: GlaxoSmithKline Pharmaceuticals Ltd has filed the outcome of its analyst/investor meeting…
Read the full analysis - Announcement under Regulation 30 (LODR)-Newspaper PublicationCompany Updatelow impact
Cruxal's analysis: GlaxoSmithKline Pharmaceuticals Ltd. has made a routine announcement regarding a…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track GlaxoSmithKline Pharmaceuticals Ltd
Cruxal reads every GlaxoSmithKline Pharmaceuticals Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.